Bibliography
- Cote T, Kelkar A, Xu K, Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov 2010;9(1):84
- Braun MM, Faragh-El-Massah S, Xu K, Cote T. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22
- Orfali M, Feldman L, Bhattacharjee V, Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Clin Pharmacol Ther 2012;92(2):262-4
- Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development : an economically viable strategy for biopharma R&D. Drug Discov Today 2012;17:13-14; 660-664
- Talele SS, Xu K, Pariser AR, Therapies for inborn errors of metabolism: what has the orphan drug act? Pediatrics 2010;126:101-6
- Thorat C, Xu K, Freeman SN, What the orphan drug act has done lately for children with rare diseases: a 10-year analysis. Pediatrics 2012;129(3):516-21
- Herper M. How a $440,000 drug is turning Alexion into a biotech's new innovation powerhouse. Forbes; 2012